EGFR and cancer: Therefore, we compared the specific targeting potential of cetuximab (an anti-EGFR antibody) functionalised AuNR in both EGFR-positive and -negative cancer cell lines and evaluated in vitro the therapeutic potential of PTT in aggressive HNSCC cells.